Series B Round of Financing
AlphaNavi Pharma Inc. (“AlphaNavi”) (Head Office: Osaka, Japan; President and CEO: Yoshihiro Oyamada) announces that it has raised a total of approximately 610 million yen through the Series B round of third-party allotment of new shares.
AlphaNavi is a biotech venture founded in January 2019 with aim to deliver novel non-opioid analgesic drugs for treatment-resistant pain diseases. AlphaNavi has licensed the manufacturing, development and marketing rights for a selective voltage-gated sodium channel Nav1.7, Nav1.8 and Nav1.9 inhibitor, ANP-230, from Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.). ANP-230 has already completed Phase 1 studies in the US, the UK and Japan and is now conducting Phase 1 / 2 study of ANP-230 for episodic infantile limb pain syndrome with mainly Nav1.9 mutation in Japan.
Episodic infantile limb pain syndrome is a rare disease with high unmet medical need, which have only episodic pain symptoms in the extremities and joints in the hand and feet. It is reported that the episodic pain was mainly caused by a gain of function mutation in the SCN11A gene (Nav1.9), and that this mutation triggered the hyper excitability of this channel localized in peripheral nerves, resulting in the onset of pain. AlphaNavi will use the funds to accelerate the clinical study and our business.
In Series B round, AlphaNavi allocated new shares to Kyoto University Innovation Capital Co., Ltd. (Head Office: Kyoto, Japan; President and CEO: Ko Kusumi), Shinsei Capital Partners Ltd. (Head Office: Tokyo, Japan; President and CEO: Manabu Nakamura), Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Hiroshi Nomura), SMBC Venture Capital Co., Ltd. (Head Office: Tokyo, Japan; President and CEO: Akira Ochiai), Nippon Venture Capital Co., Ltd. (Head Office: Tokyo, Japan; President and CEO: Minoru Tagaya), and Chushin Venture Capital Co., Ltd. (Head Office: Kyoto, Japan; President and CEO: Atsushi Yasukawa).
AlphaNavi Pharma Inc. Public Relations Div. E-mail : firstname.lastname@example.org